Lipids, diabetes, and coronary heart disease: insights from the Framingham Study, Am Heart J, vol.110, pp.1100-1107, 1985. ,
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial, Diabetes Care, vol.16, pp.434-478, 1993. ,
Use of fibrates in the metabolic syndrome: A review, World J Diabetes, vol.7, pp.74-88, 2016. ,
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing, Vasc Health Risk Manag, vol.4, pp.991-1000, 2008. ,
Peroxisome proliferator activated receptors and lipoprotein metabolism, PPAR Res, p.132960, 2008. ,
,
Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia, PPAR Res, p.924131, 2015. ,
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, vol.366, pp.1849-61, 2005. ,
Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, vol.362, pp.1563-74, 2010. ,
Effects of fibrates on cardiovascular outcomes: a systematic review and metaanalysis, Lancet, vol.375, pp.1875-84, 2010. ,
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate, p.17 ,
, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, Eur Heart J, vol.31, pp.92-101, 2010.
Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis, J Cardiovasc Pharmacol, vol.57, pp.267-72, 2011. ,
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes, JAMA Cardiol, 2016. ,
Lipidomics as a principal tool for advancing research, J Genet Genomics, vol.40, pp.375-90, 2013. ,
Lipidomics for studying metabolism, Nat Rev Endocrinol, vol.12, pp.668-79, 2016. ,
,
Lipidomics reveals a remarkable diversity of lipids in human plasma, J Lipid Res, vol.51, pp.3299-305, 2010. ,
,
Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS, J Lipid Res, vol.57, pp.509-524, 2016. ,
,
PCSK9 Association With Lipoprotein(a), Circ Res, vol.119, pp.29-35, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02429627
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment, Clin Chem, vol.54, pp.1038-1083, 2008. ,
,
, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, p.18
, baseline characteristics and short-term effects of fenofibrate, vol.64783481
, Cardiovasc Diabetol, vol.4, p.13, 2005.
,
Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry, Nat Protoc, vol.6, pp.1060-83, 2011. ,
,
, Versatile lipid profiling by liquid chromatography-high resolution mass spectrometry using all ion fragmentation and polarity switching. Preliminary application for serum samples phenotyping related to canine mammary cancer, Anal Chim Acta, vol.796, pp.75-83, 2013.
Comprehensive blood plasma lipidomics by liquid chromatography/quadrupole time-of-flight mass spectrometry, J Chromatogr A, vol.1217, pp.4087-99, 2010. ,
A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the women's health study, Clin Chem, vol.59, pp.949-58, 2013. ,
,
Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance, Diabetes, vol.62, pp.401-411, 2013. ,
,
, Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance, Diabetes, vol.58, pp.337-380, 2009.
,
,
Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study, Atherosclerosis, vol.243, pp.560-566, 2015. ,
Ceramide: a common pathway for atherosclerosis?, Atherosclerosis, vol.196, pp.497-504, 2008. ,
,
Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency, J Clin Endocrinol Metab, vol.99, pp.45-52, 2014. ,
Characterization of secretory sphingomyelinase activity, lipoprotein sphingolipid content and LDL aggregation in ldlr-/-mice fed on a high-fat diet, Biosci Rep, vol.32, pp.479-90, 2012. ,
Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin, Nat Med, vol.17, pp.55-63, 2011. ,
Dietary soy protein reduces cardiac lipid accumulation and the ceramide concentration in high-fat diet-fed rats and ob/ob mice, J Nutr, vol.139, pp.2237-2280, 2009. ,
Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment, J Clin Endocrinol Metab, vol.100, pp.2497-501, 2015. ,
Dosedependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome, Diabetes Care, vol.31, pp.1656-61, 2008. ,
Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?, Diabetes, vol.54, pp.795-802, 2005. ,
Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome, Diabetes, vol.52, pp.803-814, 2003. ,
Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL-and LDL-ApoB kinetics in type 2 diabetes, Diabetologia, vol.51, pp.1382-90, 2008. ,
Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes, J Pharmacol Exp Ther, vol.306, pp.332-339, 2003. ,
,
, Glycerophospholipid and sphingolipid species and mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study, PLoS One, vol.9, p.85724, 2014.
,
Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol, Eur Heart J, vol.37, pp.1967-76, 2016. ,
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 3 lipoprotein cholesterol; non-HDL-C, non-HDL cholesterol; TG, triglyceride, p.4 ,